Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Intestinal Microbiota Transplant (IMT) Capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Disease
1 trial -
Intraoperative Radiation Therapy in Malignant Cerebral Tumor
The First People's Hospital of Lianyungang
Glioblastoma
1 trial -
Intrathecal recombinant human alpha iduronidase
Ultragenyx UK Limited
Mucopolysaccharidosis I
1 trial -
Intravenous Nicotine
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Intravenous Vitamin C
United Therapeutics Europe Ltd
Burns
1 trial -
Intravenous administration of ferric carboxymaltose
United Therapeutics Europe Ltd
Lung Hypoxia
1 trial -
Intravenous dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aneurysm Cerebral
1 trial -
Intravenous sedation
United Therapeutics Europe Ltd
Lower Back Pain
1 trial -
Intravenous thrombolysis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
Ipilimumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
The First People's Hospital of Lianyungang
Small Cell Lung Cancer
1 trial -
Iron Isomaltoside injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Isosorbide Dinitrate 5 MG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Post-ERCP Acute Pancreatitis
1 trial -
Ivarmacitinib tablet
The First People's Hospital of Lianyungang
Polymyalgia Rheumatics (PMR)
1 trial -
Ivosidenib,Venetoclax,gilteritinib,Selinexor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
Ixekizumab+Jueyin Granules
Universal Integrated
Plaque Psoriasis
1 trial -
JAK Inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Antisynthetase Syndrome
1 trial -
JY231 Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Malignancies
1 trial -
Jianpixiaozhong particles and Wuse Dietotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Idiopathic Membranous Nephropathy
1 trial -
KL003 cell injection Drug Product
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Transfusion-dependent Beta-Thalassemia
1 trial -
Kefir peptide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Kunxian capsule
The First People's Hospital of Lianyungang
Diabetic Nephropathy
1 trial -
Kuvan
BioMarin Pharmaceutical Australia Pty Ltd
Heart Failure
1 trial -
LCAR-M61S cells preparation
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources